Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.

STOCKHOLM, May 8, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by three months for the supplemental Biologics License Application (sBLA) for a once weekly...